A specialist in the intersection of substance use and HIV sexual risk behaviors in women, Dr. Otto-Salaj says she has often been frustrated by the lack of research on what triggers risky choices. “We have some ideas, but we don’t really know for sure,” she says. Part of the problem is that the women who engage in risk behaviors often have complicated histories, involving factors such as sexual abuse and mental illness, and most studies don’t address that complexity. “ I have a feeling that the methods and interventions that we’ve been using are just too simplistic,” she says. “The result is that a lot of risk reduction interventions just don’t work as well as we’d like.”
To address this lack of information, Dr. Otto-Salaj’s team will recruit 398 African American women between the ages of 18 and 45, randomly selected from units in Milwaukee housing developments. She and her team will interview participants nine times over twelve months, asking them questions on topics such as their sexual risk, alcohol and drug use, experiences of physical and sexual abuse, current levels of victimization, personal and family history of mental illness, and violence in their communities.The team will analyze their answers, hoping to spot what leads some women pursue risk behaviors while others are resilient and avoid those risks.
Dr. Otto-Salaj will hire five or six full-time staff members to run the project. One of her main tasks, she says, is to select a project coordinator “who knows Milwaukee housing developments inside and out.” The project team will also include CABHR scientists Michael Brondino, Ph.D., Susan Rose, Ph.D., and Michael Fendrich, Ph.D.
CABHR scientists Michael Fendrich, Ph.D., Lisa Berger, Ph.D., and
Mike Brondino, Ph.D., recently received funding from UW–Madison
through the University of Wisconsin Institute for Clinical and Translational
Research.
With these funds, Drs. Fendrich, Berger and Brondino will test an
intervention to provide a combination of Buprenorphine and Nalaxone
to opioid-dependent participants in the Dane County drug court treatment
program. They will compare office-based to clinic-based delivery
of medication. The project is led by Randy Brown, M.D., of the UW–Madison
School of Medicine and Public Health.